Scisparc Ltd Asset Resilience Ratio
Scisparc Ltd asset resilience ratio. Scisparc Ltd (SPRC) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Scisparc Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Scisparc Ltd (2006–2025)
Asset resilience ratio of Scisparc Ltd from 2006 to 2025. This chart shows how Scisparc Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Scisparc Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Scisparc Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Scisparc Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Scisparc Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Scisparc Ltd Industry Peers by Asset Resilience Ratio
Compare Scisparc Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Scisparc Ltd Asset Resilience Ratio by Year (2006–2025)
Scisparc Ltd asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Scisparc Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $7.62 Million | -- |
| 2024-12-31 | 5.00% | $517.00K | $10.35 Million | -21.83pp |
| 2023-12-31 | 26.83% | $3.00 Million | $11.18 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $10.61 Million | -- |
| 2010-12-31 | 51.47% | $5.14 Million | $9.98 Million | +1.74pp |
| 2009-12-31 | 49.73% | $6.08 Million | $12.22 Million | +11.90pp |
| 2008-12-31 | 37.83% | $3.79 Million | $10.01 Million | +2.63pp |
| 2007-12-31 | 35.20% | $5.36 Million | $15.22 Million | -10.06pp |
| 2006-12-31 | 45.26% | $5.08 Million | $11.22 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more